OFIX Orthofix Medical Inc.

CIK 0000884624 50 ready 8-Ks latest July 2, 2026, 4:00 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing July 2, 2026, 4:00 PM ET

Top materiality 0.90

Event mix earnings ×18 · leadership ×12 · m_and_a ×8

Sentiment 15 pos · 6 neg · 29 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for OFIX

Highest-materiality recent filing

Orthofix and SeaSpine combine in all-stock merger of equals; 0.4163 exchange ratio, ~$693M pro forma revenue

October 11, 2022, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 5.03 item 8.01 item 9.01

SeaSpine shareholders to receive 0.4163 Orthofix shares per SPNE share; combined ownership 56.5% Orthofix, 43.5% SeaSpine.
Pro forma revenue ~$693M (trailing twelve months ended Sep 30, 2022); combined company has ~1,600 employees in 68 countries.

Read filing →

July 2, 2026, 4:00 PM ET regulatory materiality 0.65 positive item 7.01

CMS withdraws Medicare billing changes for Orthofix bone growth stimulators; reimbursement restored to prior rates

On July 1, 2026, CMS issued revised guidance withdrawing May 18, 2026 billing changes for HCPCS codes E0747, E0748, E0760.
May 21, 2026, 8:00 AM ET regulatory materiality 0.80 negative item 7.01

Orthofix cuts FY2026 guidance as CMS cuts bone stimulator reimbursement ~10%

CMS reduced Medicare reimbursement for HCPCS codes E0747, E0748, E0760 by ~10% effective May 18, 2026.
May 5, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Orthofix Q1 pro forma revenue $196.4M +2.7% constant currency; reaffirms FY guidance

GAAP net loss $(20.9)M vs $(53.1)M prior year; adjusted EBITDA $9.7M (4.9% of pro forma sales) vs $11.4M (6.0%) prior year.
April 9, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 5.02 item 9.01 ◈ Earnings Releases ×2

Orthofix reports prelim Q1 net sales $196.7M, realigns spine leadership, Reinhardt to depart

Preliminary Q1 net sales $196.7M; reported constant currency +0.4%, pro forma constant currency +2.7% YoY.
February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Orthofix Q4 net sales $219.9M, net loss narrows; FY26 guidance $850-860M sales, $95-98M adj. EBITDA

Q4 net loss $(2.2)M vs $(29.1)M YoY; adjusted EBITDA $29.2M (13.4% margin), up 230 bps.
November 4, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Orthofix Q3 pro forma net sales up 5.7%; adj EBITDA margin expands to 12.1%

Pro forma net sales $203.4M, +5.7% constant currency vs Q3 2024; reported net sales $205.6M.
August 5, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Orthofix Q2 net sales $203.1M (+2.3%); adj. EBITDA $20.6M; positive FCF; reaffirms FY25 guide

Pro forma net sales (ex-M6) $200.7M, +3.5% constant currency; net loss $(14.1)M vs $(33.4)M prior year.
May 6, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 7.01 item 9.01

Orthofix Q1 net loss $53.1M; lowers FY2025 net sales guidance to $808-816M

Q1 pro forma net sales $189.2M, up 4.3% constant currency YoY; GAAP net loss $53.1M ($1.35/share) vs $36.0M loss year ago.
February 25, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Orthofix reports record Q4 net sales of $215.7M (+8% YoY); guides FY25 sales $818-826M, adj. EBITDA $82-86M

Q4 net sales $215.7M (+8% YoY); record BGT $63.9M (+9%) and Global Orthopedics $35.8M (+18% cc).
November 8, 2024, 6:59 PM ET debt materiality 0.70 neutral item 1.01 item 1.02 item 2.03 item 9.01

Orthofix enters $275M secured credit facility with Oxford Finance; repays Blue Torch loan

New credit agreement provides $160M term loan, $65M delayed draw, and up to $50M discretionary facility, maturing Nov 2029.
November 7, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Orthofix Q3 net sales $196.6M (+7%), adjusted EBITDA $19.2M, introduces 2027 targets

Net sales $196.6M, +7% YoY; U.S. Spine Fixation +18%, U.S. Orthopedics record quarter +15%.
August 6, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Orthofix Q2 net sales $198.6M (+6% YoY); raises FY2024 guidance

Q2 net sales $198.6M, +6% YoY; net loss $(33.4M) vs $(39.4M) prior year; EPS $(0.88).
May 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Orthofix Q1: net sales $188.6M (+7.7%), net loss narrows to $36M; raises FY sales outlook to $790-795M

Net sales $188.6M, +7.7% YoY; Bone Growth Therapies +10%, U.S. Spine Fixation +16%, U.S. Orthopedics +23%.
March 5, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Orthofix Q4 net sales $200.4M (+7% pro forma constant currency); FY24 guidance implies 5-7% growth

Q4 net sales $200.4M; Bone Growth Therapies up 15% YoY; U.S. spine fixation up 13.5%.
January 9, 2024, 6:59 PM ET leadership materiality 0.80 positive item 2.02 item 5.02 item 9.01 ◈ executive_change ×2◈ Earnings Releases

Orthofix names new CEO and CFO; Q4 net sales $200.3M, pro forma up 7.5%

Massimo Calafiore appointed CEO, effective Jan 8, 2024; received $7.5M in inducement equity awards (RSUs + options).
January 8, 2024, 6:59 PM ET leadership materiality 0.65 neutral item 7.01 item 9.01

Massimo Calafiore begins as Orthofix CEO immediately; Julie Andrews named CFO effective Jan 15

Massimo Calafiore assumes role of President and CEO effective immediately and joins the Board of Directors.
December 15, 2023, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 5.02 item 8.01 item 9.01 ◈ executive_change ×3◈ Material Agreements

Orthofix enters cooperation agreement with Engine Capital; appoints three new directors

Engine Capital, holder of ~8.2% of OFIX shares, and Orthofix enter cooperation agreement.
December 1, 2023, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Orthofix names Massimo Calafiore as President and CEO; Burzić not standing for re-election

Massimo Calafiore appointed President and CEO effective early 2024, following LimaCorporate's acquisition by Enovis.
November 8, 2023, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Orthofix Q3 net sales $184M (+61% reported, +8% pro forma); GAAP EPS -$0.77, adj. $0.07

Net sales $184M, +61% reported, +8% pro forma (excl. one-time stocking order); Bone Growth Therapies +15%.
October 5, 2023, 7:59 PM ET leadership materiality 0.65 negative item 5.02 ◈ executive_change

Orthofix board member Keith Valentine resigns; interim CEO gets $825k base, $1.5M RSUs

Keith C. Valentine resigns from Board; notes disagreement with termination for cause of Valentine and others on Sept 11.
September 14, 2023, 7:59 PM ET leadership materiality 0.85 negative item 5.02 item 7.01 item 8.01 item 9.01 ◈ executive_change ×6

Orthofix terminates CEO, CFO, CLO for misconduct; appoints interim replacements

Keith Valentine, John Bostjancic, Patrick Keran fired for cause after investigation found repeated inappropriate and offensive conduct.
August 8, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Orthofix Q2 2023 revenue $187M (+7% pro forma), raises FY adjusted EBITDA guidance

Net sales $187.0M, up 58% reported / 7% pro forma constant currency YoY.
June 21, 2023, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

Orthofix enters enhanced severance agreements with CEO, CFO, and three other officers

CEO Valentine gets 1.5x salary+target bonus severance (2.99x in CiC period through Jan 2025); other executives get 1.0x (1.5x in CiC).
May 9, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

Orthofix Q1 net sales $175.2M (+65% reported, +12% pro forma CC); GAAP EPS $(1.71), adj. EPS $(0.10)

Net loss of $60.9M vs. $4.5M loss prior year; adjusted net loss $3.6M vs. adj. net income $1.0M.
March 6, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Orthofix reports Q4 2022 results; SeaSpine merger closed Jan 5; combined 2023 guidance $743-753M

Orthofix stand-alone Q4 net sales $122.2M (-2% reported, flat constant currency); net loss $7.1M vs $32.8M loss prior year.
February 13, 2023, 6:59 PM ET M&A materiality 0.60 neutral item 9.01

Orthofix files SeaSpine audited FY2021 financials: revenue $191.5M, net loss $54.3M

SeaSpine 2021 revenue $191.5M (+24% YoY); operating loss $61.0M.
January 9, 2023, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Orthofix reports Q4 net sales $122.2M (-2% YoY); SeaSpine Q4 $63.2-63.7M (+13%+); merger closed Jan 5

Orthofix Q4 net sales $122.2M, down ~2% YoY; constant currency flat; Bone Growth Therapies up ~3%.
January 5, 2023, 6:59 PM ET M&A materiality 0.75 neutral item 1.02 item 2.01 item 2.03 item 5.02 item 8.01 item 9.01 ◈ executive_change ×2◈ M&A Transactions◈ Material Agreements

Orthofix completes merger with SeaSpine; Valentine named President and CEO

Merger effective Jan 5, 2023; SeaSpine shareholders receive 0.4163 Orthofix shares per SeaSpine share (~16M shares).
January 4, 2023, 6:59 PM ET M&A materiality 0.75 positive item 5.07 ◈ Shareholder Votes

Orthofix shareholders approve stock issuance for SeaSpine merger

17.1M votes for (97.7% of votes cast); 264k against, 131k abstain.
December 5, 2022, 6:59 PM ET M&A materiality 0.75 neutral item 8.01

Orthofix board rejects revised $24/share unsolicited PE bid, reaffirms SeaSpine merger

Received unsolicited PE bid at $23/share, later revised to $24/share cash, subject to due diligence and financing.
November 30, 2022, 6:59 PM ET M&A materiality 0.75 neutral item 8.01

Orthofix receives unsolicited $23/share buyout bid, board reaffirms SeaSpine merger

Received unsolicited non-binding indication from two PE sponsors to acquire Orthofix for $23 per share cash.
November 21, 2022, 6:59 PM ET M&A materiality 0.65 positive item 8.01 item 9.01

Orthofix and SeaSpine name leadership team for combined company; John Bostjancic as CFO

Merger of equals expected to close Q1 2023, subject to shareholder approvals.
November 3, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Orthofix Q3: net sales $114M, GAAP EPS ($0.53); FY22 adj. EBITDA guidance cut; SeaSpine merger

Net sales $114.0M, up 1% reported, 5% constant currency; Global Orthopedics grew 19% constant currency.
October 11, 2022, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 5.03 item 8.01 item 9.01

Orthofix and SeaSpine combine in all-stock merger of equals; 0.4163 exchange ratio, ~$693M pro forma revenue

SeaSpine shareholders to receive 0.4163 Orthofix shares per SPNE share; combined ownership 56.5% Orthofix, 43.5% SeaSpine.
October 11, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Orthofix reports Q3 preliminary net sales $114M, up 5% CC; announces SeaSpine merger

Preliminary Q3 net sales $114M, +1% reported, +5% constant currency YoY; nine-month net sales $339M, flat reported.

Executive changes

Appointed

Vickie Capps

Director

OFIX · Orthofix Medical Inc.

Effective: 2025-03-11
Filed: March 12, 2025, 7:59 PM ET

appointed Vickie Capps as a director.

Appointed

Michael M. Finegan

Chair of the Board

OFIX · Orthofix Medical Inc.

Effective: 2024-06-18
Filed: June 20, 2024, 7:59 PM ET

At its meeting on June 18, 2024, the Company’s Board of Directors (the “Board”) unanimously appointed (i) Michael M. Finegan as Chair of the Board

Departed

Kimberley A. Elting

President, Global Orthopedics

OFIX · Orthofix Medical Inc.

Effective: 2024-07-05
Filed: June 20, 2024, 7:59 PM ET

On June 20, 2024, the Company announced that Kimberley A. Elting, the Company’s President, Global Orthopedics, will be departing as an executive and employee on or about July 5, 2024.

Departed

Catherine M. Burzik

Director

OFIX · Orthofix Medical Inc.

Filed: April 12, 2024, 7:59 PM ET

Catherine M. Burzik has confirmed to the Board, consistent with the decision announced in November 2023, that she will not stand for re-election to the Board at the Annual Meeting.

Departed

Stuart M. Essig

Director

OFIX · Orthofix Medical Inc.

Filed: April 12, 2024, 7:59 PM ET

each of Stuart M. Essig, Ph.D. and James F. Hinrichs informed the Board of Directors (the “Board”) of Orthofix Medical Inc. (the “Company”) that they have elected not to stand for re-election to the Board at the Company’s 2024 annual meeting of shareholders in June 2024 (the “Annual Meeting”).

Departed

James F. Hinrichs

Director

OFIX · Orthofix Medical Inc.

Filed: April 12, 2024, 7:59 PM ET

each of Stuart M. Essig, Ph.D. and James F. Hinrichs informed the Board of Directors (the “Board”) of Orthofix Medical Inc. (the “Company”) that they have elected not to stand for re-election to the Board at the Company’s 2024 annual meeting of shareholders in June 2024 (the “Annual Meeting”).

Appointed

Julie Andrews

Chief Financial Officer

OFIX · Orthofix Medical Inc.

Effective: 2024-01-15
Filed: January 17, 2024, 6:59 PM ET

On January 15, 2024, Julie Andrews began service as Chief Financial Officer of Orthofix Medical Inc.

Appointed

Julie Andrews

Chief Financial Officer

OFIX · Orthofix Medical Inc.

Effective: 2024-01-15
Filed: January 9, 2024, 6:59 PM ET

the Board appointed Julie Andrews as the Company’s Chief Financial Officer, effective as of January 15, 2024

Appointed

Massimo Calafiore

President and Chief Executive Officer

OFIX · Orthofix Medical Inc.

Effective: 2024-01-08
Filed: January 9, 2024, 6:59 PM ET

the Company’s Board of Directors (the “Board”) appointed Massimo Calafiore as the Company’s President and Chief Executive Officer, and Mr. Calafiore began service on such date.

Appointed

Alan Bazaar

Director

OFIX · Orthofix Medical Inc.

Effective: 2023-12-12
Filed: December 15, 2023, 6:59 PM ET

the Board has increased its size from eight to eleven directors and appointed Mr. Bazaar to the Board effective as of December 12, 2023

Appointed

Michael Finegan

Director

OFIX · Orthofix Medical Inc.

Effective: 2023-12-14
Filed: December 15, 2023, 6:59 PM ET

and Messrs. Finegan and Kummeth to the Board effective as of December 14, 2023

Appointed

Charles Kummeth

Director

OFIX · Orthofix Medical Inc.

Effective: 2023-12-14
Filed: December 15, 2023, 6:59 PM ET

and Messrs. Finegan and Kummeth to the Board effective as of December 14, 2023

Earnings & guidance

2026-Q1 EPS reported -$0.52 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

15 positive 6 negative 29 neutral

source · OFIX on sec.gov